MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LP

Vestal Point Capital LP lessened its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 280,000 shares of the biopharmaceutical company's stock after selling 550,000 shares during the quarter. Vestal Point Capital LP owned approximately 0.45% of MacroGenics worth $910,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in MacroGenics during the 4th quarter valued at approximately $32,000. American Century Companies Inc. acquired a new stake in shares of MacroGenics in the 4th quarter worth about $38,000. Jump Financial LLC acquired a new stake in shares of MacroGenics in the 4th quarter worth about $44,000. ProShare Advisors LLC lifted its position in MacroGenics by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 20,284 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 4,963 shares during the last quarter. Finally, XML Financial LLC boosted its stake in MacroGenics by 31.6% during the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 5,569 shares during the period. Institutional investors own 96.89% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HC Wainwright decreased their price objective on MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, March 25th. StockNews.com lowered MacroGenics from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Stifel Nicolaus reduced their price objective on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a report on Wednesday, May 14th. Finally, Barclays reiterated an "overweight" rating and issued a $3.00 price objective (down from $8.00) on shares of MacroGenics in a report on Wednesday. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, MacroGenics has an average rating of "Hold" and an average target price of $6.38.

MacroGenics Stock Up 2.6%

Shares of MGNX stock opened at $1.58 on Monday. The firm has a market cap of $99.68 million, a price-to-earnings ratio of -1.00 and a beta of 2.20. MacroGenics, Inc. has a 12 month low of $0.99 and a 12 month high of $5.77. The stock has a 50-day moving average price of $1.56 and a 200 day moving average price of $2.60.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The business had revenue of $13.19 million for the quarter, compared to the consensus estimate of $9.59 million. Sell-side analysts predict that MacroGenics, Inc. will post -1.06 earnings per share for the current fiscal year.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.